<DOC>
	<DOCNO>NCT02222441</DOCNO>
	<brief_summary>This study design evaluate potential effect moderate CYP3A inducer modafinil weak CYP3A inducer pioglitazone pharmacokinetics palbociclib .</brief_summary>
	<brief_title>Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib ( PD-0332991 )</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Healthy male and/or female subject non childbearing potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . Any condition possibly affect drug absorption ( eg , gastrectomy ) . Subjects selfreported history addiction , especially stimulant . A positive urine drug screen alcohol breath test . Pregnant female subject ; breastfeed female subject ; female subject childbearing potential ; male subject partner currently pregnant ; male subject childbearing potential unwilling unable use highly effective method contraception outline protocol duration study 90 day last dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Palbociclib</keyword>
	<keyword>Modafinil</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-Drug Interaction Study</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>CYP3A Inducers</keyword>
</DOC>